Pharmacotherapy of primary CNS lymphoma

REFERENCES

• BAILEY P: Intracranial sarcomatous tumorsof leptomeningeal origin. Arch. Surg. (1929) 18:1359–1402.
   Google Scholar
• RUBINSTEIN LJ: Tumors of the centralnervous system. In: Atlas of Tumor Pathology Fascicle 6. Armed Forces Institute of Pathology Washington DC, USA (1972) 215–234.
   Google Scholar
• LENNERT K: Morphology and classification of malignant lymphomas and so-called reticulosis. Acta Neuropathologica (1975) (Sunni. 6):1–16.
   Google Scholar
• EBY NL, GRUFFERMAN S, FLANNELLY CM, SCHOLD SC JR, VOGEL FS, BURGER PC: Increasing incidence of primary brain lymphoma in the US. Cancer (1988) 62:2461–2465.
   PubMed Web of Science ®Google Scholar
• LUTZ JM, COLEMAN MP: Trends in primary cerebral lymphoma. Br j Cancer (1994) 70:716–718.
   PubMed Web of Science ®Google Scholar
• O'NEILL BP, JANNEY CA, OLSON JE et al.: The continuing increase in primary central nervous system non-Hodgkin's lymphoma (PCNSL): a surveillance, epidemiology, and end results (SEER) analysis. Proc. Am. Soc. Chu. Oricol (2001) 20:53a. Abstract.
   Google Scholar
• HOCHBERG FH, MILLER DC: Primary central nervous system lymphoma. Neurosurg. (1988) 68:835–853.
   Google Scholar
• VELASQUEZ WS: Primary central nervous system lymphoma. I Neurooncol (1994) 20:177–185.
   PubMed Web of Science ®Google Scholar
• MACMAHON EM, GLASS JD, HAYWARD SD etal.: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 338:969–973.
   Google Scholar
• TRAWEEK ST: Nervous system involvement by lymphoma, leukemia and other hematopoietic cell proliferations. In: Russel] and Rubinstein's Pathology of Tumors of the Nervous System. Bigner D, McLendon R, Bruner J (Eds.), Oxford University Press (1998).
   Google Scholar
• KUMANISHI T, WASHIYAMA K, NISHIYAMA A, ABE S, SAITO T, ICHIKAWA T: Primary malignant lymphoma of the brain: demonstration of immunoglobulin gene rearrangements in four cases by the Southern blot hybridization technique. Acta Neurapathal (Berl) (1989) 79:23–26.
   Google Scholar
• TSUJINO S: lImmunoglobulin and T-cell receptor gene rearrangements as markers of lineage and clonality in malignant lymphoma]. Nippon Rinsho (2000) 58:612–617.
   Google Scholar
• HENRY JM, HEFFNER RR, JR, DILLARD SH, EARLE KM, DAVIS RL: Primary malignant lymphomas of the central nervous system. Cancer (1974) 34: 1293–1302.
   PubMed Web of Science ®Google Scholar
• ABREY LE: Primary central nervous system lymphoma. Neurologist (2000) 6:245–254.
   Google Scholar
• OSBORN A: Meningiomas and other nonglial neoplasms. In: Diagnostic Neuraradialogy Mosby (1994).
   Google Scholar
• DEANGELIS LM: Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neural (1993) 33:308–311.
   PubMed Web of Science ®Google Scholar
• SINGH A, STROBOS RJ, SINGH BM et al.: Steroid-induced remissions in CNS lymphoma. Neurology (1982) 32:1267–1271.
   PubMed Web of Science ®Google Scholar
• PIROTTE B, LEVIVIER M, GOLDMAN S, BRUCHER JM, BROTCHI J, HILDEBRAND J: Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. j Neuf-wilco] (1997) 32:63–69.
   Google Scholar
• NELSON DF, MARTZ KL, BONNER H et al: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Radiat. Once] Biol. Phys. (1992) 23:9–17.
   PubMed Web of Science ®Google Scholar
• DEANGELIS LM: Current management of primary central nervous system lymphoma. Oncology (Hentingt) (1995) 9:63–71.
   PubMedGoogle Scholar
• RAMPEN FH, VAN ANDEL JG, SIZOO W, VAN UNNIK JA: Radiation therapy in primary non-Hodgkin's lymphomas of the CNS. Eur. J. Cancer (1980) 16:177–184.
   Google Scholar
• POLLACK IF, LUNSFORD LD, FLICKINGER JC, DAMESHEK HL: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer (1989) 63:939–947.
   PubMed Web of Science ®Google Scholar
• ABREY LE, YAHALOM J, DEANGELIS LM: Treatment for primary CNS lymphoma: the next step. I Clin. Once] (2000) 18:3144-3150. ••Older patients may be treated successfullywith RT.
   Google Scholar
• DEANGELIS LM, YAHALOM J, THALER HT, KHER U: Combined modality therapy for primary CNS lymphoma. j Clin. Once] (1992) 10:635–643.
   PubMed Web of Science ®Google Scholar
• BLAY JY, CONROY T, CHEVREAU C etal.: High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. j Clin. Once] (1998) 16:864-871. •HD-MTX is the single most important chemotherapeutic agent in the treatment of PCNSL.
   Google Scholar
• RENI M, FERRERI AJ, GARANCINI MP, VILLA E: Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Once] (1997) 8:227–234.
   PubMed Web of Science ®Google Scholar
• BRADA M, DEARNALEY D, HORWICH A, BLOOM HJ: Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int. j RadMt. Once] Biol. Phys. (1990) 18:787–792.
   PubMed Web of Science ®Google Scholar
• GABBAI AA, HOCHBERG FH, LINGGOOD RM, BASHIR R, HOTLEMAN K: High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. Neurosurg. (1989) 70:190–194.
   Google Scholar
• GLASS J, GRUBER ML, CHER L, HOCHBERG FH: Pre-irradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. j Neurosurg. (1994) 81:188–195.
   PubMed Web of Science ®Google Scholar
• KIMBY E, BRANDT L, NYGREN P, GLIMELIUS BL: A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Once] (2001) 40: 198–212.
   PubMedGoogle Scholar
• NEUWELT EA, GOLDMAN DL, DAHLBORG SA et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. Clin. Once]. (1991) 9:1580–1590.
   PubMed Web of Science ®Google Scholar
• DAHLBORG SA, HENNER WD, CROSSEN JR etal.: Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J. Li. Am. (1996) 2:166. •Chemotherapy after BBB disruption is effective without RT.
   Google Scholar
• CHAMBERLAIN MC, LEVIN VA: Primary central nervous system lymphoma: a role for adjuvant chemotherapy. Neuf-mica] (1992) 14:271–275.
   Google Scholar
• CHABNER BA: Cytidine analogues. In: Cancer Chemotherapy and Biatherapy: Principles and Practice. Chabner B, Longo De (Eds.), Lippincott-Raven (1996).
   Google Scholar
• SONNEVELD P, SCHULTZ FW, NOOTER K, HAHLEN K: Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother. Pharmacy] (1986) 18:111–116.
   PubMed Web of Science ®Google Scholar
• SCHIMKE RT: Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer (1986) 57:1912–1917.
   Google Scholar
• CHU E, MOTA A, FOGARASI M: Pharmacology of cancer chemotherapy: antimetabolites. In: Cancer: Principles and Practice of Oncology DeVita VT, Hellman S, Rosenberg SA (Eds.), Philadelphia: Lippincott Williams and Wilkins (2001).
   Google Scholar
• WALKER RW, ALLEN JC, ROSEN G, CAPARROS B: Transient cerebral dysfunction secondary to high-dose methotrexate. j Clin. Once] (1986) 4:1845–1850.
   PubMed Web of Science ®Google Scholar
• VASSAL G, VALTEAU D, BONNAY M, PATTE C, AUBIER F, LEMERLE J: Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin's lymphoma. Pediatr. Hematal Once] (1990) 7:71–77.
   PubMed Web of Science ®Google Scholar
• EVANS WE, HUTSON PR, STEWART CF et al.: Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Pharmacol Ther. (1983) 33:301–307.
   Google Scholar
• HIRAGA S, ARITA N, OHNISHI T et al.:Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. (1999) 91:221–230.
   PubMed Web of Science ®Google Scholar
• BORSI JD, MOE PJ: A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer (1987) 60:5–13.
   Google Scholar
• BORSI JD, SAGEN E, ROMSLO I, SLORDAL L, MOE PJ: 7-Hydroxy-methotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol (1990) 27:164–167.
   PubMed Web of Science ®Google Scholar
• DE SMET MD: Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate. Bull. Soc. Beige. Ophtalmol (2001):91–95.
   Google Scholar
• FISHBURNE BC, WILSON DJ, ROSENBAUM JT, NEUWELT EA: Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch. Ophthalmol (1997) 115:1152–1156.
   PubMed Web of Science ®Google Scholar
• ZUNKELER B, CARSON RE, OLSON J et al.: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg. (1996) 85:1056–1065.
   PubMed Web of Science ®Google Scholar
• MCALLISTER LD, DOOLITTLE ND, GUASTADISEGNI PE et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery (2000) 46:51–60.
   PubMed Web of Science ®Google Scholar
• BLEYER AW: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat. Rep. (1977) 61:1419–1425.
   Google Scholar
• SHORE T, BARNETT MJ, PHILLIPS GL: Sudden neurologic death after intrathecal methotrexate. Med. Pediatr. arca (1990) 18:159–161.
   Google Scholar
• GEISER CF, BISHOP Y, JAFFE N, FURMAN L, TRAGGIS D, FREI E 3RD: Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood (1975) 45:189–195.
   PubMed Web of Science ®Google Scholar
• POSNER J: Neurologic complications of cancer. FA Davis, Philadelphia, USA (1995a).
   Google Scholar
• RAMU A, FUSNER JE: A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection. Isr. 1. Med. Li. (1979) 15:494–499.
   Google Scholar
• MCLAUGHLIN P, VELASQUEZ WS, REDMAN JR et al: Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. 1. Natl. Cancer Inst. (1988) 80:1408–1412.
   PubMed Web of Science ®Google Scholar
• MIKITA T, BEARDSLEY GP: Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry (1988) 27:4698–4705.
   PubMed Web of Science ®Google Scholar
• DAMON LE, PLUNKETT W, LINKER CA: Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. (1991) 51:4141–4145.
   PubMed Web of Science ®Google Scholar
• GRAHAM ML, SHUSTER JJ, KAMEN BA et al.: Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric Oncology group study. Clin. Cancer Res. (1996) 2:331–337.
   Google Scholar
• BAKER WJ, ROYER GL JR, WEISS RB: Cytarabine and neurologic toxicity. I Clin. arca (1991) 9:679–693.
   Google Scholar
• DIETS-OUWEHAND JJ, DE KEIZER RJ, VRENSEN GF, GROEN-JANSEN S, VAN BEST JA: Toxicity of 1-(beta-D-arabinofuranosyl)cytosine after intravitreal injection in the rabbit eye. Craefes Arch. Clin. Exp. Ophthalmol (1992) 230:488–495.
   Google Scholar
• STRAUCHEN JA, DALTON J, FRIEDMAN AH: Chemotherapy in the management of intraocular lymphoma. Cancer (1989) 63:1918–1921.
   PubMed Web of Science ®Google Scholar
• ZELLER P, GUTMANN H, HEGEDUS Bet al.: Methylhydrazine derivatives: a new class of cytotoxic agents. Experientia (1963) 19:129.
   Google Scholar
• COLVIN 0: Pharmacology of cancer chemotherapy: classes of alkylating agents and their properties. In: Cancer: Principles and Practice of Oncology DeVita VT, Hellman S, Rosenberg SA (Eds.), Lippincott Williams & Wilkins, Philadelphia, USA (2001).
   Google Scholar
• FINK D, AEBI S, HOWELL SB: The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. (1998) 4:1–6.
   PubMed Web of Science ®Google Scholar
• SPIVACK SD: Drugs 5 years later: procarbazine. Ann. Intern. Med. (1974) 81:795–800.
   PubMed Web of Science ®Google Scholar
• OLIVERIO VT, DENHAM C, DEVITA VT et al: Some pharmacologic properties of a new antitumor agent N-isopropyl-alpha-(2-methyl-hydrazino)-p-toluamide hydrochloride NSC-77213. Cancer Chemother. Rep. (1964) 42:1.
   PubMedGoogle Scholar
• POSNER J: Neurologic complications of cancer FA Davis, Philadelphia (1995b).
   Google Scholar
• TEW K, COLVIN M, CHABNER B: Alkylating Agents. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds.), Lippincott-Raven, Philadelphia, USA (1996):297–332.
   Google Scholar
• GIDDING CE, KELLIE SJ, KAMPS WA, DE GRAAF SS: Vincristine revisited. Crit. Rev arca Hematol (1999) 29:267–287.
   PubMed Web of Science ®Google Scholar
• JOEL S: The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Cancer Treat. Rev (1996) 21:513–525.
   Google Scholar
• ROSENTHAL S, KAUFMAN S: Vincristine neurotoxicity. Ann. Intern. Med. (1974) 80:733–737.
   PubMed Web of Science ®Google Scholar
• JACKSON DV JR, SETHI VS, SPURR CL, MCWHORTER JM: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res. (1981) 41:1466–1468.
   Google Scholar
• WHITTAKER JA, PARRY DH, BUNCH C, WEATHERALL DJ: Coma associated with vincristine therapy. Br Med. 1 (1973) 4:335–337.
   Google Scholar
• WILLIAMS ME, WALKER AN, BRACIKOWSKI JP, GARNER L, WILSON KD, CARPENTER JT: Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error. Cancer (1983) 51:2041–2047.
   Google Scholar
• KWACK EK, KIM DJ, PARK TI, CHO KR, KWON IH, SOHN YK: Neural toxicity induced by accidental intrathecal vincristine administration. 1. Korean Med. Sci. (1999) 14:688–692.
   PubMed Web of Science ®Google Scholar
• BERWICK DM: Not again! Br. Med. I (2001) 322:247–248.
   Google Scholar
• WELLER M: Glucocorticoid treatment of •• primary CNS lymphoma. J Neurooncol (1999) 43:237–239.
   PubMed Web of Science ®Google Scholar
• O'NEILL BP, HABERMANN TM, WITZIG TE, RODRIGUEZ M: Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med. Oncol (1999) 16:211–215.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• GRILLO-LOPEZ AJ, WHITE CA, DALLAIRE BK et al.: Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Cun: Pharm. Biotechnol (2000) 1:1–9.
   PubMedGoogle Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Chu. Oncol (1999) 17:268–276.
   PubMed Web of Science ®Google Scholar
• DEMIDEM A, LAM T, ALAS S, HARIHARAN K, HANNA N, BONAVIDA B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Brother. Radiopharm. (1997) 12:177–186.
   PubMed Web of Science ®Google Scholar
• RUHSTALLER TW, AMSLER U, CERNY T: Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann. Oncol (2000) 11:374–375.
   Google Scholar
• RAIZER JJ, DEANGELIS LM, ZELENETZ AD, ABREY LE: Activity of Rituximab in primary central nervous system lymphoma (PCNSL). Proc. Am. Soc. Chit. Oncol. (2000) 19:166a. Abstract.
   Google Scholar
• RUBENSTEIN JL, ROSENBERG J, DAMON LE: High dose methotrexate plus Rituximab in the treatment of primary CNS lymphoma. Neurooncology (1999) l\(Suppl. 4):336. Abstract
   Google Scholar
• RUBENSTEIN JL, MCDERMOTT M, SHUMAN MA: Intraventricular delivery of rituximab in a nonhuman primate model. Neurooncology (2000) 2\(Supp1.4):292. Abstract.
   Google Scholar
• SCHULZ H, PELS H, REHWALD U, ROSENBERG J, SCHLEGEL U, DIEHL V: Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD20 antibody IDEC-C2B8. Neurology (2001) 56\(Suppl. 8):A411. Abstract.
   Google Scholar
• TAKIMOTO C, ARBUCK S: Camptothecins. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds.), Lippincott-Raven, Philadelphia, USA (1996):463–484.
   Google Scholar
• BAKER SD, HEIDEMAN RL, CROM WR, KUTTESCH JF, GAJJAR A, STEWART CF: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol (1996) 37:195–202.
   PubMed Web of Science ®Google Scholar
• CIORDIA R, HOCHBERG F, AND BATCHELOR T: Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma. Proc. Am Soc. Chit. Oncol. (2000) 19. Abstract.
   Google Scholar
• SOUSSAIN C, SUZAN F, HOANG-XUAN K et al.: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Chit. Oncol (2001) 19:742–749.
   PubMed Web of Science ®Google Scholar
• YEH KH, CHENG AL, TIEN HF: Primary T cell leptomeningeal lymphoma--successful treatment with systemic chemotherapy. Oncology (1995) 52:501–504.
   Google Scholar
• MILLER JL: Oral temozolomide approved for refractory brain tumor. Am. J Health Syst. Pharm. (1999) 56:1910.
   Google Scholar
• RENI M, FERRERI AJ, LAND ONI C, VILLA E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl. Cancer Inst. (2000) 92:575–576.
   PubMedGoogle Scholar
• GUTIN PH, WEISS HD, WIERNIK PH, WALKER MD: Intrathecal N, N'-triethylenethiophosphoramide rthio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: Phase I-II study. Cancer (1976) 38:1471–1475.
   Google Scholar
• GUTIN PH, LEVI JA, WIERNIK PH, WALKER MD: Treatment of malignant meningeal disease with intrathecal thiotepa: a Phase II study. Cancer Treat. Rep. (1977) 61:885–887.
   PubMedGoogle Scholar
• FORSYTH PA, YAHALOM J, DEANGELIS LM: Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology (1994) 44:1473–1479.
   PubMed Web of Science ®Google Scholar
• SAND OR V, STARK-VANCS V, PEARSON D et al.: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Chu. Oncol (1998) 16:3000-3006. **Chemotherapy alone, without RT, canachieve a high complete response rate.
   Google Scholar
• SARAZIN M, AMERI A, MONJOUR A, NIBIO A, POISSON M, DELATTRE JY: Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur. J Cancer (1995) 31A:2003–2007.
   Google Scholar
• FREILICH RJ, DELATTRE JY, MONJOUR A, DEANGELIS LM: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 46:435–439.
   PubMed Web of Science ®Google Scholar
• DE SMET MD, VANCS VS, KOHLER D, SOLOMON D, CHAN CCP: Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol (1999) 83:448–451.
   PubMed Web of Science ®Google Scholar
• FISHER RI: Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Snuff]. Oncol (2000) 27:2–8.
   Google Scholar
• LACHANCE DH, BRIZEL DM, GOCKERMAN JP etal.: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology (1994) 44:1721–1727.
   Google Scholar
• MEAD GM, BLEEHEN NM, GREGOR A et al.: A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer (2000) 89:1359–1370.
   PubMed Web of Science ®Google Scholar
• SCHULTZ C, SCOTT C, SHERMAN W et al.: Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy Oncology group protocol 88-06. J Chit. Oncol (1996) 14:556–564.
   PubMed Web of Science ®Google Scholar
• CHENG AL, YEH KH, UEN WC, HUNG RL, LIU MY, WANG CH: Systemic chemotherapy alone for patients with non-Acquired Immunodeficiency Syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer (1998) 82:1946–1951.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC, LEVIN VA: Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch. Neural. (1990) 47:1113–1116.
   PubMed Web of Science ®Google Scholar
• DEANGELIS LM, SEIFERHELD W, SCHOLD SC, FISHER B, SCHULTZ CJ Combined modality treatment of primary central nervous system lymphoma (PCNSL): RTOG 93–10. Proc. Am. Soc. Chh. Orical (1999) 18:140a. Abstract
   Google Scholar
• NELSON DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). j Neuroarical (1999) 43:241–247.
   Google Scholar
• ABREY LE, DEANGELIS LM, YAHALOM J: Long-term survival in primary CNS lymphoma. j Clin. Orical (1998) 16:859–863.
   PubMed Web of Science ®Google Scholar
• CHER L, GLASS J, HARSH GR, HOCHBERG FH: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology (1996) 46:1757–1759.
   PubMed Web of Science ®Google Scholar